Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Gemcitabine in Refractory Metastatic Breast Cancer
NCT00095888Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triapine in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Confirmed response (complete or partial response) up to 6 months. Started Oct 2004; status: terminated.
02
Drugs
triapine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00095888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095888.